503 related articles for article (PubMed ID: 32250220)
1. Current, New and Future Therapeutic Targets in Inflammatory Bowel Disease: A Systematic Review.
Alimohammadi N; Koosha F; Rafeian-Kopaei M
Curr Pharm Des; 2020; 26(22):2668-2675. PubMed ID: 32250220
[TBL] [Abstract][Full Text] [Related]
2. Novel therapeutic targets for inflammatory bowel disease.
Argollo M; Fiorino G; Hindryckx P; Peyrin-Biroulet L; Danese S
J Autoimmun; 2017 Dec; 85():103-116. PubMed ID: 28711286
[TBL] [Abstract][Full Text] [Related]
3. Target-Based Small Molecule Drug Discovery Towards Novel Therapeutics for Inflammatory Bowel Diseases.
Li Y; Chen J; Bolinger AA; Chen H; Liu Z; Cong Y; Brasier AR; Pinchuk IV; Tian B; Zhou J
Inflamm Bowel Dis; 2021 Nov; 27(Suppl 2):S38-S62. PubMed ID: 34791293
[TBL] [Abstract][Full Text] [Related]
4. Application of Drug Repurposing Approach for Therapeutic Intervention of Inflammatory Bowel Disease.
Bhat MA; Usman I; Dhaneshwar S
Curr Rev Clin Exp Pharmacol; 2024; 19(3):234-249. PubMed ID: 37859409
[TBL] [Abstract][Full Text] [Related]
5. Sphingolipids as mediators of inflammation and novel therapeutic target in inflammatory bowel disease.
Sukocheva OA; Lukina E; McGowan E; Bishayee A
Adv Protein Chem Struct Biol; 2020; 120():123-158. PubMed ID: 32085881
[TBL] [Abstract][Full Text] [Related]
6. Development, validation and implementation of an in vitro model for the study of metabolic and immune function in normal and inflamed human colonic epithelium.
Pedersen G
Dan Med J; 2015 Jan; 62(1):B4973. PubMed ID: 25557335
[TBL] [Abstract][Full Text] [Related]
7. An Update on Herbal Products for the Management of Inflammatory Bowel Disease.
Arya H; Dass R; Chopra B; Kriplani P; Deswal G; Singh Grewal A; Dhingra AK; Kumar S
Antiinflamm Antiallergy Agents Med Chem; 2023; 22(1):1-9. PubMed ID: 37497699
[TBL] [Abstract][Full Text] [Related]
8. Biologic therapies against inflammatory bowel disease: a dysregulated immune system and the cross talk with gastrointestinal mucosa hold the key.
Dharmani P; Chadee K
Curr Mol Pharmacol; 2008 Nov; 1(3):195-212. PubMed ID: 20021434
[TBL] [Abstract][Full Text] [Related]
9. New insights into inflammatory bowel disease pathophysiology: paving the way for novel therapeutic targets.
Stefanelli T; Malesci A; Repici A; Vetrano S; Danese S
Curr Drug Targets; 2008 May; 9(5):413-8. PubMed ID: 18473770
[TBL] [Abstract][Full Text] [Related]
10. Inflammatory pathways of importance for management of inflammatory bowel disease.
Pedersen J; Coskun M; Soendergaard C; Salem M; Nielsen OH
World J Gastroenterol; 2014 Jan; 20(1):64-77. PubMed ID: 24415859
[TBL] [Abstract][Full Text] [Related]
11. Terpenes: Modulating anti-inflammatory signaling in inflammatory bowel disease.
Rivera Rodríguez R; Johnson JJ
Pharmacol Ther; 2023 Aug; 248():108456. PubMed ID: 37247693
[TBL] [Abstract][Full Text] [Related]
12. Therapy of inflammatory bowel disease: what to expect in the next decade.
Leiman DA; Lichtenstein GR
Curr Opin Gastroenterol; 2014 Jul; 30(4):385-90. PubMed ID: 24902037
[TBL] [Abstract][Full Text] [Related]
13. Classical and recent advances in the treatment of inflammatory bowel diseases.
Sales-Campos H; Basso PJ; Alves VB; Fonseca MT; Bonfá G; Nardini V; Cardoso CR
Braz J Med Biol Res; 2015 Feb; 48(2):96-107. PubMed ID: 25466162
[TBL] [Abstract][Full Text] [Related]
14. IBD immunopathogenesis: A comprehensive review of inflammatory molecules.
Park JH; Peyrin-Biroulet L; Eisenhut M; Shin JI
Autoimmun Rev; 2017 Apr; 16(4):416-426. PubMed ID: 28212924
[TBL] [Abstract][Full Text] [Related]
15. Current concepts of the etiology and pathogenesis of ulcerative colitis and Crohn's disease.
Sartor RB
Gastroenterol Clin North Am; 1995 Sep; 24(3):475-507. PubMed ID: 8809232
[TBL] [Abstract][Full Text] [Related]
16. NLRP3 Inhibitors as Potential Therapeutic Agents for Treatment of Inflammatory Bowel Disease.
Perera AP; Kunde D; Eri R
Curr Pharm Des; 2017; 23(16):2321-2327. PubMed ID: 28155620
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy in inflammatory bowel disease: Novel and emerging treatments.
Catalan-Serra I; Brenna Ø
Hum Vaccin Immunother; 2018; 14(11):2597-2611. PubMed ID: 29624476
[TBL] [Abstract][Full Text] [Related]
18. Modulation of sphingosine-1-phosphate in inflammatory bowel disease.
Peyrin-Biroulet L; Christopher R; Behan D; Lassen C
Autoimmun Rev; 2017 May; 16(5):495-503. PubMed ID: 28279838
[TBL] [Abstract][Full Text] [Related]
19. Natural Products: Experimental Efficient Agents for Inflammatory Bowel Disease Therapy.
Cao F; Liu J; Sha BX; Pan HF
Curr Pharm Des; 2019; 25(46):4893-4913. PubMed ID: 31840596
[TBL] [Abstract][Full Text] [Related]
20. A galectin-specific signature in the gut delineates Crohn's disease and ulcerative colitis from other human inflammatory intestinal disorders.
Papa Gobbi R; De Francesco N; Bondar C; Muglia C; Chirdo F; Rumbo M; Rocca A; Toscano MA; Sambuelli A; Rabinovich GA; Docena GH
Biofactors; 2016; 42(1):93-105. PubMed ID: 26891020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
